21.74
Exelixis Inc stock is currently priced at $21.74, with a 24-hour trading volume of 1.13M.
It has seen a -1.00% decreased in the last 24 hours and a +3.57% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $21.85 pivot point. If it approaches the $21.65 support level, significant changes may occur.
Previous Close:
$21.96
Open:
$21.86
24h Volume:
1.13M
Market Cap:
$6.33B
Revenue:
$1.85B
Net Income/Loss:
$205.05M
P/E Ratio:
76.74
EPS:
0.2833
Net Cash Flow:
$185.10M
1W Performance:
-0.64%
1M Performance:
+3.57%
6M Performance:
-6.74%
1Y Performance:
+15.76%
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
650-837-7000
Address
210 East Grand Avenue, South San Francisco, CA
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-19-23 | Initiated | BTIG Research | Buy |
Dec-15-23 | Initiated | Citigroup | Buy |
Sep-26-23 | Initiated | H.C. Wainwright | Buy |
Aug-22-23 | Reiterated | Oppenheimer | Outperform |
Aug-08-23 | Initiated | SVB Securities | Market Perform |
Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
May-10-23 | Resumed | Piper Sandler | Overweight |
Mar-09-23 | Initiated | Wells Fargo | Overweight |
Jan-26-23 | Initiated | Credit Suisse | Outperform |
Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
Nov-19-21 | Initiated | Piper Sandler | Overweight |
Nov-03-21 | Resumed | Jefferies | Buy |
Oct-07-21 | Initiated | Jefferies | Buy |
Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
Jun-15-21 | Initiated | H.C. Wainwright | Buy |
May-18-21 | Resumed | Goldman | Sell |
Mar-31-21 | Initiated | Credit Suisse | Outperform |
Mar-12-21 | Initiated | Wolfe Research | Outperform |
Mar-04-20 | Initiated | Barclays | Overweight |
Jan-13-20 | Initiated | SunTrust | Buy |
Nov-13-19 | Initiated | BofA/Merrill | Buy |
Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Sep-17-18 | Initiated | Goldman | Neutral |
Sep-10-18 | Initiated | Morgan Stanley | Underweight |
May-11-18 | Reiterated | Needham | Buy |
Oct-17-17 | Reiterated | Needham | Buy |
Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
Oct-16-17 | Reiterated | SunTrust | Buy |
Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
Sep-12-17 | Reiterated | Needham | Buy |
Jul-14-17 | Initiated | SunTrust | Buy |
Mar-31-17 | Initiated | Needham | Buy |
Mar-16-17 | Initiated | Oppenheimer | Perform |
Feb-28-17 | Downgrade | Stifel | Buy → Hold |
Nov-03-16 | Initiated | Deutsche Bank | Buy |
Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Bridgefront Capital LLC - Defense World
Defense World
Wall Street analysts' outlook for Exelixis Inc (EXEL) – Sete News - SETE News
SETE News
Exelixis Inc [NASDAQ: EXEL] Sees Increase in Stock Value – Knox Daily - Knox Daily
Knox Daily
Nomura Holdings Inc. Acquires 136,668 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Stock Position Raised by Nomura Holdings Inc. - Defense World
Defense World
Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by Seven Eight Capital LP - Defense World
Defense World
Exelixis Inc Stock (EXEL) Financials Data
Exelixis Inc (EXEL) Revenue 2024
EXEL reported a revenue (TTM) of $1.85 billion for the quarter ending March 31, 2024, a +10.98% rise year-over-year.
Exelixis Inc (EXEL) Net Income 2024
EXEL net income (TTM) was $205.05 million for the quarter ending March 31, 2024, a +33.38% increase year-over-year.
Exelixis Inc (EXEL) Cash Flow 2024
EXEL recorded a free cash flow (TTM) of $185.10 million for the quarter ending March 31, 2024, a +56.96% increase year-over-year.
Exelixis Inc (EXEL) Earnings per Share 2024
EXEL earnings per share (TTM) was $0.6433 for the quarter ending March 31, 2024, a +34.02% growth year-over-year.
About Exelixis Inc
Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited, and Invenra, Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Cap:
|
Volume (24h):